Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.67 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.62 |
| ▸ | CDK2 | P24941 | 1/20 | 0.62 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | RAF1 | P04049 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10227818 | 0.82 | EGFR (0.74) | EGFR | |
| SCHEMBL10227889 | 0.82 | EGFR (0.60) | EGFRFGFR1MKNK1 | |
| SCHEMBL5630475 | 0.82 | EGFR (0.66) | EGFRFGFR1CCNA2CDK2CCNA1 | |
| SCHEMBL10227854 | 0.80 | EGFR (0.55) | EGFR | |
| Hydrochloric Acid SCHEMBL2196386 | 0.80 | EGFR (0.54) | EGFR | |
| SCHEMBL5630686 | 0.79 | CCNA2 (0.57) | EGFRFGFR1CCNA2CDK2CCNA1 | |
| SCHEMBL2193915 | 0.79 | EGFR (0.52) | EGFRFGFR1CCNA2CDK2CCNA1 | |
| SCHEMBL938649 | 0.79 | EGFR (0.79) | EGFRFGFR1CCNA2CDK2CCNA1 | |
| SCHEMBL938202 | 0.78 | EGFR (0.74) | EGFRFGFR1CCNA2CDK2CCNA1 | |
| SCHEMBL2086491 | 0.78 | EGFR (0.74) | EGFRFGFR1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799653-B1 | Condensed thienopyrimidine derivatives for the treatment of cancer | BAYER IP GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| EP-1799653-B1 | Condensed thienopyrimidine derivatives for the treatment of cancer | BAYER IP GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110053928-A1 | PYRIMIDOTHIENOINDAZOLES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-03 | — | — | US | disclosed |
| US-20110053928-A1 | PYRIMIDOTHIENOINDAZOLES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-03 | — | — | US | disclosed |
| US-20070299066-A1 | Novel Pyrimidothienoindazoles | BAYER PHAMACEUTICALS CORPORATION (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299066-A1 | Novel Pyrimidothienoindazoles | BAYER PHAMACEUTICALS CORPORATION (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299066-A1 | Novel Pyrimidothienoindazoles | BAYER PHAMACEUTICALS CORPORATION (US) | 2007-12-27 | — | — | US | disclosed |
| EP-1819711-A2 | PYRIMIDOTHIENOINDAZOLES CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR | Bayer Pharmaceuticals Corporation (US) | 2007-08-22 | — | — | EP | disclosed |
| US-7238701-B2 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238701-B2 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238701-B2 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-20060293322-A1 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-12-28 | — | — | US | disclosed |
| EP-1651652-B1 | SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORP (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006055268-A2 | PYRIMIDOTHIENOINDAZOLES CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299066-A1 | Novel Pyrimidothienoindazoles | CCNI, TPMT, TYMP | EGFR 4006/4885FGFR1 2067/4885CCNA2 29/4885 |
| US-20110053928-A1 | PYRIMIDOTHIENOINDAZOLES | CCNI, TPMT, TYMP | EGFR 3262/4885FGFR1 1980/4885CCNA2 31/4885 |
| US-20110172224-A1 | NOVEL HETEROCYCLES | CCNI, PCNA, CCNA1 | EGFR 2146/4885FGFR1 1058/4885CCNA2 5/4885 |
| US-20060293322-A1 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | MKI67, PCNA, MYC | EGFR 1499/4885FGFR1 149/4885CCNA2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.